Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTXNYSE / NASDAQHealthcareLarge cap

$515.02-$5.64 (-1.1%)

Last close · Data as of Nov 20, 2026

Market cap
$112.1B
P/E
28.4x
EV / EBITDA
22.4x
Revenue
$12.0B
Net margin
32.9%
ROCE
20.9%

+22.0% over the last year

Vertex Pharmaceuticals Incorporated price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+0.1%
3M
-4.7%
6M
+19.6%
1Y
+22.0%
5Y
+181.6%

52-week range

Day change -$5.64 (-1.1%) from $521 to $515 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in VRTX, bought on each weekday since 2021.

News & filings

What Vertex Pharmaceuticals Incorporated filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was more than a hundred times interest costs.

Concerns (1)

  • The P/E of 28.4 is 36% above the peer median of 20.8.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

Read moreShow less

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Shares outstanding
255.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$112.1B
P/E
28.4x
P/B
6.0x
EV / EBITDA
22.4x
EV / Sales
9.1x
P/S
9.3x
52-week high
$558.88
52-week low
$422.32

Profitability

Operating margin
37.9%
Net margin
32.9%
EBITDA margin
40.5%
ROE
21.2%
ROCE
20.9%
ROA
15.4%
Asset turnover
0.47

Growth

Revenue
$12.0B
Revenue growth, 1Y
8.9%
Revenue CAGR, 3Y
10.4%
Net profit growth, 1Y
-838.1%
Free cash flow
$3.2B

Solvency

Current ratio
2.90
Debt / Equity
0.11
Debt / Assets
0.08
CFO / Net profit
0.92
Cash / Market cap
4.5%

Where the revenue went

Of every $100 of FY2025 revenue, $33 was left as net income.

Vertex Pharmaceuticals Incorporated income statement flow, FY2025
Vertex Pharmaceuticals Incorporated income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$1.7B
RevenueGross profit$10.3B
Gross profitResearch and development$4.0B
Gross profitSelling, general and administrative$1.8B
Gross profitOther operating expenses$0.00
Gross profitOperating income$4.6B
Operating incomePretax income$4.6B
Interest and other incomePretax income$88.8M
Pretax incomeTax and other$690.0M
Pretax incomeNet income$4.0B

Revenue and net profit

Revenue grew 8.9% in FY2025; net profit is the dashed line.

Vertex Pharmaceuticals Incorporated revenue and net profit by fiscal year
Vertex Pharmaceuticals Incorporated revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$8.9B$3.3B
FY2023$9.9B$3.6B
FY2024$11.0B-$535.6M
FY2025$12.0B$4.0B

Cash flows

FY2025: $3.6B from operations, $3.2B free after investment (dashed).

Vertex Pharmaceuticals Incorporated operating and free cash flow by fiscal year
Vertex Pharmaceuticals Incorporated operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$4.1B$3.9B
FY2023$3.5B$3.3B
FY2024-$492.6M-$978.0M
FY2025$3.6B$3.2B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$12.0B+8.9%1Y
EBITDA
$4.9B+900.7%1Y
Net profit
$4.0B
Cash from operations
$3.6B
Free cash flow
$3.2B
Revenue CAGR, 3Y
10.4%
Net profit CAGR, 3Y
6.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$12.0B$4.9B$4.0B$3.2B21.2%+8.9%-838.1%

Monthly returns

Month-by-month returns of VRTX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$25.6B
Liabilities$7.0B
Equity$18.7B
Paid-in capital$5.1B
Retained earnings$13.6B

Market cap against peers

8 peers: same sector, nearest by size.

  1. Vertex Pharmaceuticals Incorporated (this company)$112.1B

Peers map

Healthcare companies placed by value, growth and quality; VRTX highlighted.

P/E against peers

VRTX trades at 28.4x earnings against a peer median of 20.8x (a 36% premium).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Vertex Pharmaceuticals IncorporatedVRTXthis companyP/E ↑ premium$112.1B28.4x6.0x21.2%22.4x
Danaher CorporationDHR$132.1B36.6x2.5x6.9%21.2x
CVS Health CorporationCVS$121.0B68.4x1.6x2.4%19.5x
Bristol-Myers Squibb CompanyBMY$115.6B16.4x6.3x38.2%10.0x
Stryker CorporationSYK$115.5B35.6x5.2x14.5%20.2x
Medtronic plcMDT$105.2B22.6x2.2x9.7%14.3x
McKesson CorporationMCK$91.0B19.1x-41.9x-219.2%13.3x
Elevance Health, Inc.ELV$88.9B15.7x2.0x12.9%—
HCA Healthcare, Inc.HCA$80.3B11.8x-13.3x-112.6%8.2x
Peer median—20.8x2.1x8.3%14.3x

Year-to-date ROI

VRTX since 1 January, against earlier years.

Historical volatility

VRTX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Vertex Pharmaceuticals Incorporated operating margin by fiscal year
Vertex Pharmaceuticals Incorporated operating margin by fiscal year
DateOperating margin
FY202247.6%
FY202338.3%
FY2024-2.1%
FY202537.9%
LineFY2025
Cost of revenueCost Of Revenue$1.7B
Gross profitGross Profit$10.3B
Operating expensesOperating Expense$5.8B
Research and developmentResearch And Development$4.0B
Selling, general and administrativeSelling General And Administration$1.8B
Total expensesTotal Expenses$7.4B
Pretax incomePretax Income$4.6B

Learn while you research

Academy chapters picked for Vertex Pharmaceuticals Incorporated and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →